 |
Assessing 5-year incidence rates and determinants of osteoporotic fractures in primary care |
F. Lapia, M. Simonettib, R. Michieli, A. Pasqua, M.L. Brandi, B. Frediani, C. Cricelli, G. Mazzaglia |
|
Genetic architecture of hand quantitative ultrasound measures: A population-based study in a Sardinian genetic isolate |
G. Biino, L. Casula, F. de Terlizzi, M. Adamo, S. Vaccargiu, M. Francavilla, D. Loi, A. Casti, M. Atzori, M. Cosso, F. Marras, C. Cepollaro, M. L. Brandi, M. Pirastu |
|
Genetic Determinants of Osteoporosis: Common Bases to Cardiovascular Diseases? |
F. Marini, M. L. Brandi |
|
Paget's disease of bone: there's more than the affected skeletal--a clinical review and suggestions for the clinical practice. |
A. Falchetti, L. Masi, M. L. Brandi |
|
Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw |
F. Marini, P. Tonelli, L. Cavalli, T. Cavalli, L. Masi, A. Falchetti, M. L. Brandi |
|
Pharmacogenetics of osteoporosis |
F. Marini, M. L. Brandi |
|
What is a good patient reported outcome after total hip replacement? |
N.K. Arden, A. Kiran, A. Judge, L.C. Biant, M.K. Javaid, D.W. Murray, A.J. Carr, C. Cooper, R.E. Field |
|
Does birthweight predict bone mass in adulthood? A systematic review and meta-analysis. |
J. Baird, M. A. Kurshid, M. Kim, N. Harvey, E. Dennison, C. Cooper |
|
Facilitated transporters mediate net efflux of amino acids to the fetus across the basal membrane of the placental syncytiotrophoblast |
J. K. Cleal, J. D. Glazier, G. Ntani, S. R. Crozier, P. E. Day, N. C. Harvey, S. M. Robinson, C. Cooper, K. M. Godfrey, M. A. Hanson, R. M. Lewis |
|
Increased fat mass is associated with increased bone size but reduced volumetric density in pre pubertal children |
Z.A. Cole, N.C. Harvey, M. Kim, G. Ntani, S.M. Robinson, H.M. Inskip, K.M. Godfrey, C. Cooper, E.M. Dennison, The Southampton Women's Survey Study Group |
|
Objective measures of physical capability and subsequent health: a systematic review |
R. Cooper, D. Kuh, C. Cooper, C. R. Gale, D. A. Lawlor, F. Matthews, R. Hardy, The Falcon and Halcyon Study Teams |
|
Secular trends in the incidence of hip and other osteoporotic fractures |
C. Cooper, Z. A. Cole, C. R. Holroyd, S. C. Earl, N. C. Harvey, E. M. Dennison, L. J. Melton, S. R. Cummings, J. A. Kanis, The IOF CSA Working Group on Fracture Epidemiology |
|
Epigenetic influences in the developmental origins of osteoporosis |
C. Holroyd, N. Harvey, E. Dennison, C. Cooper |
|
Growth in childhood predicts hip fracture risk in later life |
M. K. Javaid, J. G. Eriksson, E. Kajantie, T. Forsén, C. Osmond, D. J. P. Barker, C. Cooper |
|
Coordinator-based systems for secondary prevention in fragility fracture patients |
D. Marsh, K. Akesson, D. E. Beaton, E. R. Bogoch, S. Boonen, M.-L. Brandi, A. R. McLellan, P. J. Mitchell, J. E. M. Sale, D. A. Wahl, IOF CSA Fracture Working Group |
|
Association of vitamin D status with knee pain and radiographic knee osteoarthritis |
S. Muraki, E. Dennison, K. Jameson, B.J. Boucher, T. Akune, N. Yoshimura, A. Judge, N.K. Arden, K. Javaid, C. Cooper |
|
Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study |
S. Pouwels, A. Lalmohamed, P. Souverein, C. Cooper, B. J. Veldt, H. G. Leufkens, A. de Boer, T. van Staa, F. de Vries |
|
Bisphosphonate use and risk of post-operative fracture among patients undergoing a total knee replacement for knee osteoarthritis: a propensity score analysis |
D. Prieto-Alhambra, M. K. Javaid, A. Judge, J. Maskell, A. Kiran, C. Cooper, N. K. Arden |
|
Changes in hip fracture rate before and after total knee replacement due to osteoarthritis: a population-based cohort study |
D. Prieto-Alhambra, M. K. Javaid, J. Maskell, A. Judge, M. Nevitt, C. Cooper, N. K. Arden |
|
Fracture Risk Before and After Total Hip Replacement in Patients With Osteoarthritis |
D. Prieto-Alhambra, M. K. Javaid, A. Judge, J. Maskell, A. Kiran, F. de Vries, C. Cooper, N. K. Arden |
|
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report |
R. Rizzoli, K. Akesson, M. Bouxsein, J. A. Kanis, N. Napoli, S. Papapoulos, J.-Y. Reginster, C. Cooper |
|
Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW) |
E. S. Siris, S. Gehlbach, J. D. Adachi, S. Boonen, R. D. Chapurlat, J. E. Compston, C. Cooper, P. Delmas, A. Díez-Pérez, F. H. Hooven, A. Z. LaCroix, J. C. Netelenbos, J. Pfeilschifter, M. Rossini, C. Roux, K. G. Saag, P. Sambrook, S. Silverman, N. B. Watts, A. Wyman, S. L. Greenspan |
|
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards |
S. Vasikaran, R. Eastell, O. Bruyère, A. J. Foldes, P. Garnero, A. Griesmacher, M. McClung, H. A. Morris, S. Silverman, T. Trenti, D. A. Wahl, C. Cooper, J. A. Kanis, for the IOF-IFCC Bone Marker Standards Working Group |
|
Life course body mass index and risk of knee osteoarthritis at the age of 53 years: evidence from the 1946 British birth cohort study |
A. K. Wills, S. Black, R. Cooper, R. J. Coppack, R. Hardy, K. Remmes Martin, C. Cooper, D. Kuh |
|
A FRAX® model for the assessment of fracture probability in Belgium |
H. Johansson, J. A. Kanis, E. V. McCloskey, A. Odén, J.-P. Devogelaer, J.-M. Kaufman,A. Neuprez, M. Hiligsmann, O. Bruyere, J.-Y. Reginster |
|
Adverse Reactions and Drug-Drug Interactions in the Management of Women with Postmenopausal Osteoporosis |
R. Rizzoli, J.-Y. Reginster, S. Boonen, G. Bréart, A. Diez-Perez, D. Felsenberg, J.-M. Kaufman, J. A. Kanis, C. Cooper |
|
Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies |
P. Miossec, C. L. Verweij, L. Klareskog, C. Pitzalis, A. Barton, F. Lekkerkerker, S. Reiter, A. Laslop, F. Breedveld, E. Abadie, B. Flamion, W. Dere, S. Mpofu, N. Goel, D. Ethgen, B. Mitlak, S. Ormarsdóttir, R. Rao, Y. Tsouderos, J.-Y. Reginster; on behalf of the Group for the Respect of Ethics and Excellence in Science (GREES) |
|
The potential impact of new National Osteoporosis Foundation guidance on treatment patterns |
B. Dawson-Hughes, A. C. Looker,A. N. A. Tosteson, H. Johansson, J. A. Kanis, L. J. Melton III |
|
Automatic Human Knee Cartilage Segmentation From 3-D Magnetic Resonance Images |
P. Dodin, J.-P. Pelletier, J. Martel-Pelletier, F. Abram |
|
Development and validation of a disease model for postmenopausal osteoporosis |
A. Gauthier, J. A. Kanis, M. Martin, J. Compston, F. Borgström, C. Cooper, E. McCloskey; On behalf of the Committee of Scientific Advisors, International Osteoporosis Foundation |
|
FRAX - modell för att beräkna 10-årsrisken för fraktur |
H. Johansson, J. A. Kanis, Ö. Ljunggren, O. Ström, O. Svensson, D. Mellström |
|
Osteoporosis |
J. A. Kanis |
|
Case finding for the management of osteoporosis
with FRAX®-assessment and intervention thresholds for the UK |
J. A. Kanis, E. V. McCloskey, H. Johansson, O. Ström, F. Borgström, A. Oden, National Osteoporosis Guideline Group |
|
Guidance for the adjustment of FRAX according to the dose of glucocorticoids |
J. A. Kanis, H. Johansson, A. Oden, E. V. McCloskey |
|
Development and use of FRAX® in osteoporosis |
J. A. Kanis, E. V. McCloskey, H. Johansson, A. Oden, O. Strom, F. Borgstrom |
|
Osteoporosis - Clinical Review |
J. A. Kanis, E. V. McCloskey |
|
Towards a diagnostic and therapeutic consensus in male osteoporosis |
J. A. Kanis, G. Bianchi, J. P. Bilezikian, J.-M. Kaufman, S. Khosla, E. Orwoll, E. Seeman |
|
Targeting subchondral bone for treating osteoarthritis: what is the evidence? |
S. Kwan Tat, D. Lajeunesse, J.-P. Pelletier, J. Martel-Pelletier. |
|
Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement |
W. D. Leslie, L. M. Lix, H. Johansson, A. Oden, E. McCloskey, J. A. Kanis |
|
Independent Clinical Validation of a Canadian FRAX Tool: Fracture Prediction and Model Calibration |
W. D. Leslie, L. M. Lix, H. Johansson, A. Oden, E. V. McCloskey, J. A. Kanis for the Manitoba Bone Density Program |
|
Hip fracture risk in older US adults by treatment eligibility status based on new National Osteoporosis Foundation guidance |
A. C. Looker, B. Dawson-Hughes, A. N. A. Tosteson, H. Johansson, J. A. Kanis, L. J. Melton III |
|
Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis |
J.-P. Pelletier, J.-P. Raynauld, J. Caron, F. Mineau, F. Abram, M. Dorais, B. Haraoui, D. Choquette, J. Martel-Pelletier |
|
Risk factors predictive of joint replacement in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: results from over 6 years of observation |
J.-P. Raynauld, J. Martel-Pelletier, B. Haraoui, D. Choquette, M. Dorais, L. M. Wildi, F. Abram, J.-P. Pelletier; for the Canadian Licofelone Study Group |
|
Adverse Reactions and Drug-Drug Interactions in the Management of Women with Postmenopausal Osteoporosis |
R. Rizzoli, J.-Y. Reginster, S. Boonen, G. Bréart, A. Diez-Perez, D. Felsenberg, J.-M. Kaufman, J. A. Kanis, C. Cooper |
|
Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts |
S. Kwan Tat, J.-P. Pelletier, F. Mineau, J. Caron, J. Martel-Pelletier |
|
hondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI |
L. M. Wildi, J.-P. Raynauld, J. Martel-Pelletier, A. Beaulieu, L. Bessette, F. Morin, F. Abram, M. Dorais, J.-P. Pelletier |
|
Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES) |
O. Bruyère, R. Rizzoli, V. Coxam, B. Avouac, T. Chevalier, V. Fabien-Soulé, J. A. Kanis, J.-M. Kaufman, Y. Tsouderos, J.-Y. Reginster |
|
The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES) |
O. Bruyère, J. A. Kanis, M.-E. Ibar-Abadie, N. Alsayed, M. L. Brandi, N. Burlet, D. L. Cahall, A. Chines, J.-P. Devogelaer, W. Dere, N. Goel, N. Hughes, J.-M. Kaufman, S. Korte, B. H. Mitlak, D. Niese, R. Rizzoli, L. C. Rovati, J.-Y. Reginster |
|
Loading and Skeletal Development and Maintenance |
P. Bergmann, J. J. Body, S. Boonen, Y. Boutsen, J.-P. Devogelaer, S. Goemaere, J. Kaufman, J.-Y. Reginster, S. Rozenberg |
|
Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA |
J. S. Smolen, M. Boers, E. C. Abadie, F. C. Breedveld, P. Emery, T. Bardin, N. Goel, D. J. Ethgen, B. P. Avouac, W. H. Dere, P. Durez, M. Matucci-Cerenic, B. Flamion, A. Laslop |
|
Medication Compliance and Persistence: Terminology and Definitions |
J. A. Cramer, A. Roy, A. Burrell, C. J. Fairchild, M. J. Fuldeore, D. A. Ollendorf, P. K. Wong |
|
A Competing Risks Prescription Refill Model of Compliance and Persistence |
T. I. Barron, K. Bennett, J. Feely |
|
Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club |
J.-J Body, P. Bergmann, S. Boonen, Y. Boutsen, J.-P. Devogelaer, S. Goemaere, J.-M. Kaufman, S. Rozenberg, J.-Y. Reginster |
|
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis |
R. Rizzoli, N. Burlet, D. Cahall, P. D. Delmas, E. F. Eriksen, D. Felsenberg, J. Grbic, M. Jontell, R. Landesberg, A. Laslop, M. Wollenhaupt, S. Papapoulos, O. Sezer, M. Sprafka, J.-Y. Reginster |
|
The role of calcium and vitamin D in the management of osteoporosis |
R. Rizzoli, S. Boonen, M.-L. Brandi, N. Burlet, P. Delmas, J.-Y. Reginster |
|
European regulatory perspectives for innovative therapies |
S. Ormarsdottir, J.-Y. Reginster, E. Abadie |
|
Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system |
O. Bruyère, N. Burlet, P. D. Delmas, R. Rizzoli, C. Cooper and J.-Y. Reginster |
|
Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science |
J. Compston, D.M. Reid, J. Boisdron, M.-L. Brandi, N. Burlet, D. Cahall, P.D. Delmas, W. Dere, J.-P. Devogelaer, L.A. Fitzpatrick, B. Flamion, N. Goel, S. Korte, A. Laslop, B. Mitlak, S. Ormarsdottir, J. Ringe, R. Rizzoli, Y. Tsouderos, T. Van Staa, J.-Y. Reginster |
| |
Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women |
O. Bruyere, A. R. Varela, S. Adami, J. Detilleux, V. Rabenda, M. Hiligsmann, J.-Y. Reginster |
|
Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity |
P. Musette, M. L. Brandi, P. Cacoub, J. M. Kaufman, R. Rizzoli, J.-Y. Reginster |
|
Management of osteoporosis in the elderly |
R. Rizzoli, O. Bruyere, J. B. Cannata-Andia, J.-P. Devogelaer, G. Lyritis, J. D. Ringe, B. Vellas, J.-Y. Reginster |
|
Post-fracture management of patients with hip fracture: a perspective |
O. Bruyere, M.-L. Brandi, N. Burlet, N. Harvey, G. Lyritis, H. Minne, S. Boonen, J.-Y. Reginster, R. Rizzoli and K. Akesson |
|
European guidance for the diagnosis and management of osteoporosis in postmenopausal women |
J. A. Kanis, N. Burlet, C. Cooper, P. D. Delmas, J.-Y. Reginster, F. Borgstrom, R. Rizzoli |
|
Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women |
V. Rabenda, R. Mertens, V. Fabri, J. Vanoverloop, F. Sumkay, C. Vannecke, A. Deswaef, G. A. Verpooten, J.-Y. Reginster |
|
Adherence to treatment of osteoporosis: a need for study |
F. Lekkerkerker, J. A. Kanis, N. Alsayed, G. Bouvenot, N. Burlet, D. Cahall, A. Chines, P. Delmas, R.-L. Dreiser, D. Ethgen, N. Hughes, J.-M. Kaufman, S. Korte, G. Kreutz, A. Laslop, B. Mitlak, V. Rabenda, R. Rizzoli, A. Santora, R. Schimmer, Y. Tsouderos, P. Viethel, J.-Y. Reginster |
|
Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis |
J. Goldhahn, W. H. Scheele, B. Mitlak, E. Abadie, P. Aspenberg, P. Augat, M.-L. Brandi, N. Burlet, A. Chines, P. D. Delmas, I. Dupin-Roger, D. Ethgen, B. Hanson, F. Hartl, J. Kanis, R. Kewalramani, A. Laslop, D. Marsh, S. Ormarsdottir, R. Rizzoli, A. Santora, G. Schmidmaier, M. Wagener, J.-Y. Reginster |
|
Critical Issues in Translational and Clinical Research for the Study of New Technologies to Enhance Bone Repair |
J. Goldhahn, B. Mitlak P. Aspenberg, J. Kanis, R. Rizzoli, J.-Y. Reginster |
|
Low Incidence of Anti-Osteoporosis Treatment After Hip Fracture |
V. Rabenda, J. Vanoverloop, V. Fabri, R. Mertens, F. Sumkay, C. Vannecke, A. Deswaef, G. A. Verpooten, J.-Y. Reginster |
|
Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence |
V. Rabenda, M. Hiligsmann, J.-Y. Reginster |
|
Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures |
V. Rabenda, J.-Y. Reginster |
|
Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men |
J.-Y. Reginster, E. Abadie, P. Delmas, R. Rizzoli, W. Dere, P. der Auwera, B. Avouac, M.-L. Brandi, A. Daifotis, A. Diez-Perez, G. Calvo, O. Johnell, J.-M. Kaufman, G. Kreutz, A. Laslop, F. Lekkerkerker, B. Mitlak, P. Nilsson, J. Orloff, M. Smillie, A. Taylor, Y. Tsouderos, D. Ethgen, B. Flamion |
|
Therapeutic Adherence with Bisphosphonates in the Treatment of Osteoporosis |
V. Rabenda, J.-Y. Reginster |
|
Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women |
O. Bruyere, A. R. Varela, S. Adami, J. Detilleux,V. Rabenda, M. Hiligsmann, J.-Y. Reginster |
